Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ONVO
- Price
- 2.12
- Stock movement down
- -0.05 (-2.30%)
- Company name
- Organovo Holdings Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.71M
- Ent value
- 2.61M
- Price/Sales
- 26.36
- Price/Book
- 0.74
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -19.06%
- 1 year return
- -82.85%
- 3 year return
- -64.07%
- 5 year return
- -53.58%
- 10 year return
- -44.81%
Last updated: 2025-04-05
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ONVO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 26.36 |
| Price to Book | 0.74 |
| EV to Sales | 25.38 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.28M |
| EPS (TTM) | -8.36 |
| FCF per share (TTM) | -7.89 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 103.00K |
| Gross profit (TTM) | -112.00K |
| Operating income (TTM) | -12.77M |
| Net income (TTM) | -12.54M |
| EPS (TTM) | -8.36 |
| EPS (1y forward) | -16.44 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -108.74% |
| Operating margin (TTM) | -12398.06% |
| Profit margin (TTM) | -12176.70% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.17M |
| Net receivables | 29.00K |
| Total current assets | 4.78M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 1.63M |
| Total assets | 6.75M |
| Accounts payable | 419.00K |
| Short/Current long term debt | 1.17M |
| Total current liabilities | 2.41M |
| Total liabilities | 3.07M |
| Shareholder's equity | 3.68M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.82M |
| Capital expenditures (TTM) | 13.00K |
| Free cash flow (TTM) | -11.83M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -340.82% |
| Return on Assets | -185.70% |
| Return on Invested Capital | -299.12% |
| Cash Return on Invested Capital | -282.16% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.04 |
| Daily high | 2.14 |
| Daily low | 1.96 |
| Daily Volume | 64K |
| All-time high | 3060.00 |
| 1y analyst estimate | 64.80 |
| Beta | 0.61 |
| EPS (TTM) | -8.36 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ONVO | S&P500 | |
| Current price drop from All-time high | -99.93% | -17.56% |
| Highest price drop | -99.93% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -80.21% | -11.07% |
| Avg time to new high | 85 days | 12 days |
| Max time to new high | 2862 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.71M
Marketcap category
Small-cap
Description
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
Employees
12
Website
Investor relations
SEC filings
CEO
Taylor J. Crouch
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page